Adjusted Hazard Ratios for Mortality and Morbidity With Follow-Up From February 23, 1994, to December 31, 2017
obesity, death, CVD, atherosclerotic CVD, diabetes
OBESITY, MYOCARDIAL INFARCTION, STROKE, CARDIOVASCULAR DISEASE, CVD, REGRESSION, HEART FAILURE, CORONARY HEART DISEASE, TYPE 2 DIABETES, DIABETES
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease.Adjusted for age 65 years or older at trial baseline, sex, race, Hispanic ethnicity, educational attainment, smoking status, treatment with antihypertensive drugs prior to trial baseline, obesity at trial baseline, atherosclerotic CVD at trial baseline, other atherosclerotic CVD at trial baseline, participation in Lipid Lowering Trial, diabetes status at trial baseline, high-density lipoprotein cholesterol less than 35 mg/dL (to convert to millimoles per liter, multiply by 0.0259) at trial baseline, estimated glomerular filtration rate less than 60 mL/min/1.73 mFatal or nonfatal confirmed CVD included hospitalization or death due to myocardial infarction, stroke, or heart failure.Statistically significant at Significant interactions with in-trial period were found. Amlodipine vs chlorthalidone: non-CVD mortality, Alhough the candidate covariates for some models differed when LASSO-penalized regression methods were applied as a variable selection procedure, the resulting AHRs were nearly identical to those that were produced from the full multivariable model, and the 95% CIs were of comparable width (eTables 5-7 in Subgroup analyses by age, sex, race and ethnicity, and type 2 diabetes status demonstrated consistent results with overall analyses for most outcomes, including CVD mortality (eFigures 2A-C in 